Sponsor Dossier
Arrotex Pharmaceuticals
Sponsor Dossier for Arrotex Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ABACAVIR/LAMIVUDINE
- Brand: ACARBOSE
- Brand: ACICLOVIR AN
- Brand: Actacode
- Brand: ACTILAX
- Brand: AGILOCAM
- Brand: AH
- Brand: ALENDRO
- Device (sponsor): Lubricant, eye
- Device (sponsor): Nail treatment solution
- Device (sponsor): Cold treatment spray
- Device (sponsor): Cryogenic spray, cutaneous
- Device (sponsor): Nail treatment solution
- Device (sponsor): Irrigation fluid, nasal
- Device (sponsor): Sexual lubricant
- Device (sponsor): Lubricant, eye
- Device (sponsor): Irrigation kit, nasal
- Device (sponsor): Irrigation fluid, nasal
- Device (sponsor): Nail treatment solution
About
Arrotex Pharmaceuticals is an Australian Private Company with ABN 30605552234, registered in Victoria. The company is currently active and registered for GST.
Portfolio
Arrotex Pharmaceuticals maintains a portfolio of 1001 brands on the ARTG, of which 420 have cleared the SEO quality gate. The portfolio includes 383 brands with Product Information on file, 88 brands with at least one PBS-listed item, 38 brands with PBAC outcomes on record, and 4 brands with AusPARs on record.
Therapeutic focus
The portfolio is distributed across the following therapeutic areas: — Neurology: 270 brands — Cardiology: 174 brands — Infectious Disease: 132 brands — Oncology: 67 brands — Ophthalmology: 50 brands — Endocrinology: 48 brands — Immunology: 44 brands — Pain & Anaesthesia: 43 brands — Gastroenterology: 34 brands — Urology: 21 brands — Psychiatry: 17 brands — Respiratory: 17 brands — Complementary Medicine: 16 brands — Dermatology: 16 brands — Women's Health: 15 brands — Reproductive Health: 13 brands — Haematology: 11 brands — Pain Management: 5 brands — Musculoskeletal: 4 brands — Other: 2 brands — Renal: 1 brand — Rare Disease: 1 brand
PBS footprint
Eighty-eight brands in the Arrotex Pharmaceuticals portfolio are PBS-listed, with the portfolio touching the PBS schedule as recently as 1 May 2026.
Regulatory activity
The most recent PBAC outcome in the Arrotex Pharmaceuticals portfolio dates to 1 November 2025, with 38 brands holding PBAC outcomes on record. The most recent AusPAR dates to 8 June 2021, with 4 brands holding AusPARs on record.